This content is from: Premium Citadel’s Quiet Drug Fix The hedge fund firm has been quietly making private investments in biopharma. By Steve Taub August 30, 2019
This content is from: Premium Tiger Global Poised to Benefit From Peloton IPO Here’s what’s at stake for Tiger Global’s venture capital business when Peloton goes public. By Steve Taub August 29, 2019
This content is from: Premium Hedge Funds Cling to Most Popular Stocks An analysis of hedge fund portfolios found little turnover in top U.S. long equity positions. By Steve Taub August 27, 2019
This content is from: Premium Sachem Head’s Portfolio Is Bigger Than You May Think There’s more to Sachem Head’s portfolio than what appears in its second-quarter 13F filing. By Steve Taub August 23, 2019
This content is from: Premium The Hedge Funds Poised to Profit From a Drug Maker’s IPO At least four hedge funds own nearly half of the shares of the latest biopharma company planning to go public. By Steve Taub August 22, 2019
This content is from: Premium Third Point Adds to Gain in June The activist firm recently stepped up pressure on Sony and United Technologies. By Steve Taub July 03, 2019
Sponsored The Evolving Asset Owner Investment Model The reasons for managing investments in-house are clear – but the right operational infrastructure to support the investment process is crucial to success. Sponsored by Northern Trust October 10, 2019
Sponsored Traders Should Be Watching This Weekly Government Report Sponsored by CME Group October 07, 2019
